Catalog No.
Product Name
Application
Product Information
Citations
-
Tubulin Inhibitor
FC-116 is a potent tubulin inhibitor that disrupts microtubule dynamics, leading to the inhibition of colorectal cancer (CRC) cell proliferation. It demonstrates significant activity with IC50 values of 4.52 nM in HCT116 cells and 18.69 nM in CT26 cells. By inducing endoplasmic reticulum stress and generating excess reactive oxygen species (ROS), FC-116 promotes mitochondrial damage and apoptosis in CRC cells. This compound also exhibits substantial anti-tumor effects in vivo, making it a valuable reagent for colorectal cancer research. -
Tubulin Inhibitor
Taltobulin trifluoroacetate is a potent tubulin inhibitor that targets microtubule dynamics. This synthetic analogue of hemiasterlin effectively inhibits the polymerization of purified tubulin, leading to disrupted microtubule organization within cells. Taltobulin trifluoroacetate induces mitotic arrest and apoptosis, making it a valuable compound for research in cancer biology and studies focused on overcoming P-glycoprotein-mediated drug resistance. -
Microtubule-destabilizing Agent
Antiproliferative agent-23 is a microtubule-destabilizing agent that disrupts the tubulin-microtubule system. It induces apoptosis through a mitochondrion-dependent mechanism by downregulating Bcl-2, while upregulating Bax and Cyt c proteins, thereby activating the caspase cascade. Additionally, antiproliferative agent-23 triggers reactive oxygen species (ROS)-mediated endoplasmic reticulum stress in A549/CDDP cells via the PERK/ATF4/CHOP signaling pathway, demonstrating significant anti-tumor activity. This compound is suitable for research applications aimed at understanding cancer biology and therapeutic interventions. -
Antimicrotubule Chemotherapy Agent
Estramustine phosphate is an estradiol analog that functions as an orally active antimicrotubule chemotherapy agent. By binding to microtubule-associated proteins (MAPs) and/or tubulin, it depolymerizes microtubules, disrupting mitosis and promoting cell death through apoptosis. This compound is predominantly utilized in cancer research, particularly for studies related to prostate cancer. -
IDO/Tubulin Inhibitor
IDO/Tubulin-IN-2 is a potent inhibitor targeting both indoleamine 2,3-dioxygenase (IDO) and tubulin. This compound exhibits significant anticancer activity, demonstrated by its effect on various cell lines, including U87, HepG2, A549, HCT-116, and LO2, with IC50 values of 0.43, 0.036, 0.041, 0.095, and 1.04 μM, respectively. IDO/Tubulin-IN-2 is valuable for research applications in cancer biology, particularly in elucidating mechanisms of tumorigenesis and therapeutic resistance. -
Tubulin Polymerization Inhibitor
Tubulin polymerization-IN-61 is a potent tubulin polymerization inhibitor that disrupts microtubule dynamics, leading to the destruction of the microtubule skeleton. This compound effectively blocks the cell cycle at the G2/M phase, inducing apoptosis and inhibiting cancer cell migration and colony formation. In preclinical studies, Tubulin polymerization-IN-61 demonstrates significant antitumor activity in the 4T1 xenograft model, highlighting its potential for cancer research and therapeutic applications. -
Tubulin Polymerization Inhibitor
Tubulin Inhibitor 33 is a tubulin polymerization inhibitor that disrupts microtubule assembly in a dose-dependent manner, with an IC50 of 9.05 μM. This compound exhibits significant antitumor activity by promoting apoptosis in cancer cells. Tubulin Inhibitor 33 is a valuable reagent for research focusing on cancer biology and the mechanisms of tumorigenesis. -
Tubulin/MMP Inhibitor
Tubulin/MMP-IN-2 is a dual inhibitor targeting both tubulin and matrix metalloproteinases (MMPs). It effectively inhibits tubulin polymerization, leading to induced apoptosis in cancer cells. Additionally, Tubulin/MMP-IN-2 demonstrates inhibitory activity against MMP-2, MMP-3, and MMP-9, with IC50 values of 24.95 μM, 31.60 μM, and 22.37 μM, respectively. This compound is valuable for research focused on cancer biology and therapeutic development. -
Tubulin Ligand
SL-3-19 is a tubulin ligand that inhibits microtubule assembly, leading to significant antitumor activity against esophageal squamous cell carcinoma (ESCC) in both in vitro and in vivo models. This compound induces G2/M phase cell cycle arrest and apoptosis, while also disrupting tumor vascularization. SL-3-19 serves as a valuable reagent for research focused on ESCC and related malignancies. -
Microtubule-Binding Molecule
Myoseverin is a microtubule-binding molecule that acts as an angiogenesis inhibitor. This compound induces the reversible fission of multinucleated myotubes into mononucleated fragments, thereby affecting muscle cell dynamics. Additionally, Myoseverin demonstrates anti-angiogenic properties by inhibiting both endothelial cell function and the differentiation of endothelial progenitor cells. Its unique mechanism makes it a valuable tool for research in muscle biology and vascular development. -
Integrin αvβ6 Inhibitor
MORF-627 is a selective integrin αvβ6 inhibitor that effectively impairs TGF-β1 activation and pSMAD2 signaling. This compound significantly decreases collagen deposition and markers of epithelial-mesenchymal transition in fibrotic cells, demonstrating notable antifibrotic activity in idiopathic pulmonary fibrosis models without causing genotoxicity. While MORF-627 induces bladder epithelial proliferation and early invasive urothelial carcinoma in cynomolgus monkeys and human cells, these toxic effects can be mitigated by exogenous TGF-β. This reagent is valuable for investigating the pathological mechanisms underlying pulmonary fibrosis and assessing associated drug safety. -
Tubulin Inhibitor
Antiproliferative agent-30 is a tubulin inhibitor that disrupts tubulin assembly and effectively inhibits FLT3 and Abl1 activity. This compound demonstrates impressive antiproliferative effects against various cancer cell lines, exhibiting IC50 values of 0.054 nM, 0.008 nM, and 0.144 nM for HCT-116, K562, and MV-4-11 cells, respectively. Additionally, Antiproliferative agent-30 shows potential in targeting acute myeloid leukemia (AML) cells with FLT3-ITD-TKD mutations, highlighting its significance in cancer research and potential therapeutic applications. -
Microtubule Inhibitor
MPT0B002 is a potent microtubule inhibitor that targets tubulin polymerization, leading to significant anticancer effects. This compound induces apoptosis and effectively arrests the cell cycle at the G2/M phase. MPT0B002 is useful in various cancer research applications, providing insights into microtubule dynamics and the mechanisms of tumor cell proliferation. -
Tubulin/VEGFR Inhibitor
Tubulin/VEGFR-2-IN-2 is an orally active inhibitor targeting tubulin and VEGFR-2, exhibiting IC50 values of 3.27 μM and 0.09 μM, respectively. This compound demonstrates significant antitumor activity by enhancing reactive oxygen species generation, disrupting mitochondrial membrane potential, inducing apoptosis, and arresting the cell cycle. Additionally, Tubulin/VEGFR-2-IN-2 possesses anti-angiogenic effects, impairing endothelial cell migration, invasion, and tube formation in vitro. It effectively suppresses angiogenesis, tumor growth, and metastasis in vivo, making it a valuable tool for research involving non-small cell lung cancer, breast cancer, gastric cancer, and lymphoma. -
Tubulin polymerization Inhibitor
Tubulin polymerization-IN-11 is a potent inhibitor of tubulin polymerization with an IC50 value of 3.4 μM. It demonstrates significant antiproliferative activity by inducing apoptosis and causing cell cycle arrest at the G2/M phase. Mechanistically, Tubulin polymerization-IN-11 reduces the expression levels of cyclin B1, phosphorylated cdc2, and Bcl-2 while increasing the expression of cleaved PARP, making it valuable for research in cancer biology and cell cycle regulation. -
Tubulin Polymerization Inhibitor
Tubulin Inhibitor 17 is a potent tubulin polymerization inhibitor, demonstrating an IC50 value of 12.38 µM. This compound exhibits significant anticancer activity by inducing apoptosis in tumor cells. It is suitable for research applications focused on cancer biology and the study of microtubule dynamics. -
Microtubule Inhibitor
4SC-207 is a potent microtubule inhibitor that induces cell cycle arrest and apoptosis by obstructing microtubule growth. This compound effectively inhibits tumor cell proliferation both in vitro and in vivo, demonstrating significant activity against taxane-resistant xenograft mouse models. 4SC-207 is suitable for cancer research applications, particularly in the study of colon adenocarcinoma and other malignancies. -
Tubulin/HDAC Inhibitor
Tubulin/HDAC-IN-1 is a dual inhibitor targeting tubulin and histone deacetylase 8 (HDAC8) through CH/π interaction and hydrogen bonding, respectively. This compound effectively inhibits tubulin polymerization and selectively inhibits HDAC8 with an IC50 value of 150 nM. Tubulin/HDAC-IN-1 demonstrates cytotoxic effects against a range of human cancer cell lines, induces cell cycle arrest in the G2/M phase, and promotes apoptosis. It is a valuable reagent for research involving hematologic malignancies and solid tumors, including neuroblastoma and leukemia. -
Tubulin Polymerization Inhibitor
Tubulin polymerization-IN-28 is a selective inhibitor of microtubule protein polymerization, primarily targeting tubulin. This compound demonstrates significant anticancer activity by activating NQO1, leading to the release of combretastatin A-4, which promotes apoptosis in tumor cells. Tubulin polymerization-IN-28 is valuable for research applications focused on cancer therapy and the mechanisms of cell death. -
Tubulin Polymerization Inhibitor
Tubulin polymerization-IN-60 is a tubulin polymerization inhibitor that targets the colchicine binding site on tubulin, effectively disrupting microtubule assembly. This compound induces cell cycle arrest at the G2/M phase, leading to increased apoptosis in cancer cells. It serves as a valuable tool in cancer research, enabling the study of microtubule dynamics and the development of novel therapeutic strategies against malignant tumors. -
Tubulin Inhibitor
Tubulin polymerization-IN-9 is a potent inhibitor of tubulin polymerization, exhibiting an IC50 value of 1.82 μM. This compound effectively induces cell cycle arrest at the G2/M phase and triggers apoptosis in K562 cells, accompanied by depolarization of mitochondria. Tubulin polymerization-IN-9 demonstrates significant anti-vascular and antitumor activities, making it a valuable tool in cancer research and therapeutic studies. -
Tubulin Inhibitor
Tubulin Inhibitor 23 is a potent inhibitor of tubulin with an IC50 value of 4.8 µM. This compound induces apoptosis in cancer cells and exhibits antiangiogenic activity in a dose-dependent manner. Tubulin Inhibitor 23 is relevant for research applications related to leukemia and other malignancies involving aberrant angiogenesis and cell proliferation. -
Tubulin Polymerization Inhibitor
Tubulin polymerization-IN-13 is an inhibitor of tubulin polymerization, exhibiting an IC50 of 0.37 μM. This compound demonstrates significant anti-proliferative activity against various cancer cell lines, inducing apoptosis and potentially exhibiting antivascular properties. It serves as a valuable tool for research focused on cancer therapeutics and the mechanisms of cell division. -
Tubulin Inhibitor
Tubulin Inhibitor 14 targets NQO2 (quinone oxidoreductase 2) and exhibits a potent inhibitory effect with an IC50 of 1.0 μM. It disrupts tubulin polymerization and impedes the formation of capillary-like structures in endothelial cells. This microtubule-destabilizing agent possesses potential tumor-selectivity and exhibits antiangiogenic and vascular-disruptive properties, making it valuable for research in cancer biology and angiogenesis. -
Tubulin polymerization Inhibitor
Tubulin polymerization-IN-4 is a potent inhibitor of tubulin polymerization, exhibiting an IC50 value of 4.6 μM. This compound effectively disrupts tubulin dynamics, leading to cell cycle arrest at the G2/M phase, induction of apoptosis, and inhibition of both clonogenesis and migration in HeLa cells. Tubulin polymerization-IN-4 serves as a valuable tool in research related to cervical cancer, facilitating the exploration of therapeutic strategies targeting tubulin dynamics. -
Tubulin Inhibitor
Disorazol A is a potent tubulin inhibitor that disrupts microtubule formation by hindering tubulin polymerization. This action effectively blocks mitosis, leading to cell cycle arrest at the G2/M phase and subsequent induction of apoptosis. Additionally, Disorazol A has demonstrated inhibitory effects on L929 mouse fibroblasts, with an IC50 value of 3 pM, and promotes the accumulation of p53 protein within the nucleus. This compound holds potential for research in cancer biology and therapeutic applications. -
Tubulin/NRP1 Inhibitor
Tubulin/NRP1-IN-1 is a dual inhibitor targeting tubulin and neuropilin-1 (NRP1), exhibiting IC50 values of 0.71 μM and 0.85 μM, respectively. This compound effectively decreases the viability of prostate tumor cell lines and promotes apoptotic processes. Its unique mechanism makes it a valuable tool for studying cancer biology and exploring potential therapeutic strategies. -
Tubulin Polymerization Inhibitor
Tubulin polymerization-IN-14 is a selective inhibitor of tubulin polymerization, exhibiting an IC50 of 3.15 μM. This compound demonstrates significant anti-vascular and anticancer activities by inducing apoptosis in cancer cells. It is particularly valuable in research focused on cancer biology and therapeutic drug development targeting microtubule dynamics. -
Microtubule/Tubulin Inhibitor
SSE1806 is a microtubule/tubulin inhibitor derived from podophyllotoxin, exhibiting notable anticancer and antiproliferative effects. It demonstrates a GI50 range of 1.29-21.15 μM against cancer cell growth, inducing mitotic abnormalities and G2/M phase cell cycle arrest. Additionally, SSE1806 enhances p53 expression and effectively inhibits the growth of colon cancer organoids, while also overcoming multidrug resistance in MDR-1 overexpressing cell lines, making it a valuable tool for cancer research. -
PAK1 Inhibitor
ZMF-10 is a potent PAK1 inhibitor, exhibiting an IC50 of 174 nM for PAK1 and varying potencies for related isoforms PAK2 and PAK3 at 1.038 µM and 1.372 µM, respectively. This compound effectively inhibits PAK1 activity, influencing PAK1-regulated processes such as apoptosis, ER stress response, and cellular migration in MDA-MB-231 breast cancer cells. ZMF-10 is suitable for investigations into mechanisms of anticancer therapy and related cellular pathways. -
Tubulin Polymerization Inhibitor
KY216 is a potent tubulin polymerization inhibitor that targets the colchicine-binding site of tubulin, with an IC50 value of 2.61 μM. This compound demonstrates significant biological activity in hindering tubulin polymerization, making it a valuable tool for research applications in non-small cell lung cancer (NSCLC) and breast cancer studies. KY216's mechanism of action positions it as a promising candidate for further investigation into therapeutic strategies against these malignancies. -
Tubulin Polymerization Inhibitor
5HPP-33 is a potent inhibitor of tubulin polymerization with an IC50 of 8.1 μM. It demonstrates significant anti-proliferative activity against leukemia and multiple myeloma cells, exhibiting IC50 values ranging from 1 to 10 μM. 5HPP-33 effectively induces cell cycle arrest at the G2/M phase and promotes apoptosis, making it a valuable tool for cancer research and therapeutic studies targeting microtubule dynamics. -
Microtubule Inhibitor
Kribb3 is a microtubule inhibitor that effectively disrupts microtubule dynamics. It demonstrates significant biological activity by inhibiting cancer cell proliferation with a GI50 range of 0.2-2.5 μM, promoting G2/M phase cell cycle arrest, and inducing apoptosis in HCT-116 cells. Additionally, Kribb3 has shown promising antitumor activity in murine models, making it a valuable tool for cancer research. -
Microtubule Polymerization Inhibitor
UA62784 is a microtubule polymerization inhibitor that selectively interacts with tubulin dimers. As a specific inhibitor of centromere protein E (CENP-E) kinesin, UA62784 is valuable for studying its role in cell division. This compound is particularly relevant for research applications focused on pancreatic cancer and its underlying molecular mechanisms. -
Microtubule Protein Polymerization Inhibitor
AB8939 is a potent microtubule protein polymerization inhibitor that exhibits significant anti-tumor activity, with an IC50 of less than 10 nM against tumor cell proliferation. This compound effectively circumvents resistance mechanisms associated with P-glycoprotein and myeloperoxidase. AB8939 also induces G2/M phase cell cycle arrest and triggers apoptosis in affected cells, making it a valuable tool for cancer research and therapeutic development. -
Microtubule/Tubulin Inhibitor
Sabizabulin hydrochloride is a potent microtubule inhibitor that interacts specifically with the colchicine binding site on tubulin. This compound has demonstrated significant antitumor activity, exhibiting an average IC50 of 5.2 nM in melanoma and prostate cancer cell lines. Its pharmacological profile indicates a low risk of adverse effects, making it a promising candidate for research in cancer therapeutics. -
Tubulin Inhibitor
Tubulin inhibitor 35 is a dual inhibitor targeting tubulin polymerization and topoisomerase I, with an IC50 of approximately 5.69 μM and 50 μM, respectively. This compound demonstrates significant anti-tumor activity, effectively inhibiting the migration and invasion of MGC-803 and RKO cell lines, and inducing apoptosis by arresting the cell cycle at the G2/M phase. With potent efficacy against gastrointestinal tumors, Tubulin inhibitor 35 exhibits an IC50 of 0.09 μM in MGC-803 and 0.2 μM in RKO cell lines, making it a valuable reagent for cancer research applications. -
Tubulin Polymerization Inhibitor
Tubulin polymerization-IN-31 is a tubulin polymerization inhibitor with an IC50 of 3.64 μM. This compound interferes with microtubule dynamics, leading to the induction of apoptosis in cancer cells. Its antitumor activity makes it a valuable tool for investigating cancer biology and developing therapeutic strategies targeting microtubule-dependent processes. -
Microtubule Inhibitor
DAT-230 is a microtubule inhibitor that induces cell apoptosis by promoting microtubule de-polymerization and causing G2/M phase cell cycle arrest. This compound effectively inhibits cell growth both in vitro and in vivo, making it valuable for studies on cancer cell proliferation and the mechanisms of action related to microtubule dynamics. Researchers can utilize DAT-230 to explore therapeutic strategies targeting microtubule function in various cellular contexts. -
Tubulin Inhibitor
Tubulin-IN-51 is a potent tubulin inhibitor with an IC50 of 31 nM, demonstrating oral bioavailability. It promotes tubulin polymerization in vitro and uniquely does not compete with Paclitaxel for binding sites, while inhibiting the interaction of Vinblastine with tubulin. This compound effectively downregulates the G1 phase of the cell cycle and induces apoptosis, leading to significant tumor growth inhibition in various nude mouse xenograft models. Tubulin-IN-51 is valuable for research in cancer biology and therapeutic applications targeting microtubule dynamics. -
Microtubule-Stabilizing Agent
Discodermolide is a potent microtubule-stabilizing agent that exerts its effects by binding to tubulin and enhancing microtubule polymerization, leading to G2/M phase cell cycle arrest and apoptosis in cancer cells. With a Ki of 0.4 μM, it effectively inhibits cancer cell proliferation, including those resistant to Paclitaxel. Discodermolide is a valuable tool for research on breast and colon cancer, providing insights into microtubule dynamics and potential therapeutic strategies. -
Tubulin Inhibitor
Tubulin Inhibitor 13 is a potent compound that targets tubulin polymerization, exhibiting an IC50 value of 16.1 μM. It effectively inhibits cancer cell migration and invasion, promotes apoptosis, and displays significant anticancer activity. Its mechanisms make it a valuable tool for research into cancer biology and potential therapeutic applications. -
Microtubule Disruptor
6-MOMIPP is a microtubule disruptor that acts on the colchicine site of β-tubulin. It effectively induces mitotic arrest and subsequent cell apoptosis. This compound demonstrates significant activity against the viability of various cancer cell lines, including glioblastoma, melanoma, and lung carcinoma. 6-MOMIPP is a valuable tool for cancer research, enhancing the understanding of microtubule dynamics in tumor biology. -
Tubulin Inhibitor
Tubulin Inhibitor 32 is a potent agent targeting tubulin, demonstrating significant anti-proliferative effects through the inhibition of microtubule polymerization. This compound induces apoptosis and causes cell cycle arrest at the G2/M phase, making it a valuable tool for cancer research. Its anti-tumor activity further supports its potential applications in studying cancer cell dynamics and therapeutic resistance. -
β-microtubulin Inhibitor
Tubulin inhibitor 43 is a potent β-microtubulin inhibitor that exhibits significant antitumor activity. By impeding β-microtubulin function, it effectively disrupts cancer cell proliferation and growth, ultimately leading to the induction of apoptosis. This compound is valuable for research applications focused on cancer biology and therapeutic development. -
Tubulin and Bmi-1 Inhibitor
APD-94 is a dual inhibitor that targets both tubulin and Bmi-1, disrupting normal tubulin polymerization. This compound downregulates Bmi-1 expression, leading to cell cycle arrest at the G2/M phase and subsequent induction of apoptosis in cancer cells. APD-94 effectively inhibits cancer cell proliferation and demonstrates growth repression of HT29 cell xenografts in NOD/SCID mice. Its applications are particularly relevant in the study of colorectal cancer. -
Tubulin Polymerization Inhibitor
Tubulin polymerization-IN-22 is a potent inhibitor of tubulin polymerization, exhibiting an IC50 of 8.1 μM. This compound effectively arrests the cell cycle at the G2/M phase and induces apoptosis in various cell lines. Its utility in research applications includes studying cell cycle regulation and the mechanisms of apoptosis. -
Tubulin Inhibitor
N-Deacetyl-N-formylcolchicine is a potent inhibitor targeting the colchicine-binding site of tubulin. This compound demonstrates significant antiproliferative activity across multiple cancer cell lines, with IC50 values ranging from 32.61 to 100.28 nM. By inhibiting microtubule polymerization, N-Deacetyl-N-formylcolchicine effectively blocks cell division, induces apoptosis in cancer cells, and suppresses cellular migration. Its application is particularly relevant in the research of lung cancer and various solid tumors. -
Tubulin Polymerization Inhibitor
Tubulin polymerization-IN-43 is a potent tubulin polymerization inhibitor that effectively disrupts cellular microtubule networks by binding to the Colchicine site. This compound promotes cell cycle arrest at the G2/M phase and induces apoptosis in leukemia cells, thereby demonstrating significant anti-cancer activity. Additionally, Tubulin polymerization-IN-43 has been shown to inhibit angiogenesis, making it a valuable tool for cancer research and therapeutic development. -
Tubulin Inhibitor
S-72 is a potent tubulin inhibitor that disrupts tubulin polymerization, leading to mitotic phase cell cycle arrest and apoptosis in cancer cells. Additionally, S-72 has been shown to suppress STAT3 signaling, making it a valuable tool for investigating mechanisms of cancer cell proliferation and survival. Its ability to target both microtubule dynamics and critical signaling pathways highlights its potential in cancer research.
